In a survey of 29 U.S. patient groups [3], New Scientist found only two ruled out drug company funding. Seven of the patient groups [4] surveyed received less than 5% of their income from drug companies, while others [5] were reliant on them for over one-third of their budget. The Colorectal Cancer Coalition receives approximately 81% of its budget from drug companies while a PR consultant for the Neuropathy Association claimed funding sources was "proprietary" information. Joel Lexchin, from York University in Toronto, Canada said "groups should publicise how much money they've gotten from which companies and what it is used for." Even though patient groups dismiss the idea that funding influences their advocacy, Lexchin is unpersuaded: "psychologists talk about the 'gift relationship'. The patient organisations are getting something and feel the need to repay that gift. Whether they are conscious of it or not is really irrelevant."